Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMS 2023 | Managing renal failure in patients with multiple myeloma

Efstathios Kastritis • 27 Sep 2023
IMS 2023
Multiple Myeloma Antibodies Bortezomib Carfilzomib Cyclophosphamide Daratumumab Dexamethasone Pomalidomide Selinexor

Efstathios Kastritis, MD, University of Athens, Athens, Greece, proposes treatment and management strategies for patients with multiple myeloma who exhibit renal failure, highlighting the value of incorporating anti-CD38 monoclonal antibodies (mAbs) when treating these patients.This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Efstathios Kastritis

Monitoring, diagnosing & managing cardiotoxicity in AL amyloidosis 0:52
Monitoring, diagnosing & managing cardiotoxicity in AL amyloidosis
Efstathios Kastritis • 29 May 2024
The outcomes of patients with AL amyloidosis and end-stage renal disease 1:44
The outcomes of patients with AL amyloidosis and end-stage renal disease
Efstathios Kastritis • 29 Jun 2024
Differentiating between amyloidosis and myeloma 1:22
Differentiating between amyloidosis and myeloma
Efstathios Kastritis • 29 May 2024
Unmet needs that remain in stage 3B and R/R amyloidosis 1:26
Unmet needs that remain in stage 3B and R/R amyloidosis
Efstathios Kastritis • 29 May 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals